HPV16E7抗原的HLA-A2限制性细胞毒性T淋巴细胞表位的筛选与鉴定  

Screening and Identification of Predicted Epitopes of HLA-A2-restricted Cytotoxic T Lymphocytes Derived from the HPV16 E7 Antigen

作　　者：徐云升[1] 郝飞[1] 宋志强[1] 钟白玉[1] 郝进[1] 叶庆佾[1] 

机构地区：[1]第三军医大学西南医院皮肤科

出　　处：《中华皮肤科杂志》2004年第5期283-284,共2页Chinese Journal of Dermatology

基　　金：国家自然科学基金(30070698)

摘　　要：目的筛选和鉴定人工合成的人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞预测表位。方法对预测的E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞(CTL)表位运用标准Fmoc方案进行合成与纯化,采用标准51Cr释放试验检测特异性CTL诱导活性。结果筛选并鉴定出E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)2条人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性CTL表位。结论E711-19(YMLDLQPET)和E749-57(RAHYNIVTF)抗原性较强,有可能作为HPV感染治疗用肽疫苗的候选表位。Objective To screen and identify the predicted epitopes of synthesized predicted HLA-A2-restricted cytotoxic T lymphocytes (CTLs) derived from HPV16 E7 antigen. Methods The predicted epitopes of HLA-A2-restricted CTLs derived from HPV16 E7 antigen were synthesized and purified with Standard Fmoc assays, and the standard 51Cr release assay was used to determine their activities to induce specific CTL. Results Two epitopes of HLA-A2-restricted CTLs, namely E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) derived from HPV16 E7 antigen were identified. Conclusion E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) have antigenicity, and may be the candidates for development of peptide vaccine in the treatment of HPV infections.

关 键 词：HPV16 E7抗原 HLA-A2 限制性细胞毒性 T淋巴细胞表位 筛选 鉴定 检测 人乳头瘤病毒16型 

分 类 号：R392[医药卫生—免疫学]